To provide the information your oncologist is not telling you or doesn't have the time to!
In oncology, where the stakes are often life and death, it’s easy to focus on clinical precision and measurable outcomes. Yet, the human side of medicine—the compassion, connection, and understanding we bring to patients and their families—can have just as profound an impact. Reading the deeply moving Art of Oncology piece published in the NEJM …
Colorectal cancer remains a significant global health challenge, ranking as the third most common cancer and the second leading cause of cancer-related deaths worldwide. Among metastatic colorectal cancer patients, the subset with microsatellite instability-high (MSI-H) or mismatch-repair–deficient (dMMR) tumors presents unique opportunities for immunotherapy. The recent CheckMate 8HW trial, published in the New England Journal …
While this article is aimed at healthcare providers, its message of gratitude and reflection is for anyone seeking inspiration this Thanksgiving. This Thanksgiving weekend feels profoundly different for me—a special opportunity to step back, reflect, and express gratitude. After 13 years of service at Orlando Health, I made a life-changing decision to resign and rediscover …
Spending three to four weeks in Japan with my family has been a transformative experience. From the bustling streets of Tokyo to the historic temples of Kyoto, the serene deer-filled parks in Nara, and the vibrant food scenes in Osaka, this trip has been as educational as it’s been enjoyable. Beyond the stunning landscapes and …
For patients with advanced melanoma who have exhausted standard treatment options, new therapies offer much-needed hope. On November 21, 2024, Replimune Group, Inc. announced that its breakthrough oncolytic immunotherapy, RP1 (vusolimogene oderparepvec), in combination with nivolumab, received Breakthrough Therapy Designation from the FDA. The FDA also accepted a Biologics License Application (BLA) for RP1 under …
On November 20, 2024, the FDA granted accelerated approval to zanidatamab-hrii (Ziihera), a bispecific HER2-directed antibody, for the treatment of previously treated, unresectable, or metastatic HER2-positive biliary tract cancer (BTC). This decision brings new hope for patients battling this aggressive and hard-to-treat disease, offering a targeted option for a population with limited therapeutic choices. The …
Electrolytes—essential minerals such as calcium, potassium, and magnesium—play a critical role in maintaining various physiological functions. In oncology, the importance of monitoring and managing electrolytes cannot be overstated. Electrolyte imbalances can not only signal the presence of malignancies but also influence the safety and efficacy of cancer treatments. This blog explores the significance of key …
Radiation therapy has long been a cornerstone in the treatment of various cancers, including gastric cancer, particularly for locally advanced or high-risk cases. However, the evolving landscape of gastric cancer management has raised questions about the necessity of adding preoperative chemoradiotherapy to standard perioperative chemotherapy. The recently published TOPGEAR trial sheds new light on this …
In the world of oncology, the old adage holds true: “When tumors are the rumors and cancer is possibly the answer, then tissue is the issue.” This highlights the critical role of biopsy in uncovering the true nature of suspicious lesions. Hepatic tumors, in particular, pose a diagnostic challenge because they encompass a broad spectrum …
Bladder cancer, particularly muscle-invasive bladder cancer (MIBC), poses significant treatment challenges due to its high recurrence rate and aggressive nature. Traditionally, neoadjuvant chemotherapy followed by surgery (radical cystectomy) has been the standard of care for cisplatin-eligible patients. However, researchers have been exploring ways to improve outcomes by incorporating immunotherapy into treatment. A recent phase 3 …